Attovia Therapeutics (NASDAQ:ATTO) Issues Earnings Results

Attovia Therapeutics (NASDAQ:ATTO) announced its quarterly earnings data on Wednesday. The company reported ($4.88) EPS for the quarter, Zacks reports.

Attovia Therapeutics Price Performance

Shares of ATTO traded up $0.91 during midday trading on Wednesday, reaching $23.13. 81,162 shares of the stock were exchanged, compared to its average volume of 262,593. Attovia Therapeutics has a 52 week low of $16.15 and a 52 week high of $24.32.

Analyst Upgrades and Downgrades

ATTO has been the topic of a number of recent research reports. Royal Bank Of Canada began coverage on Attovia Therapeutics in a report on Monday. They issued an “outperform” rating and a $45.00 target price on the stock. Citigroup started coverage on shares of Attovia Therapeutics in a report on Monday. They set a “buy” rating and a $30.00 price objective on the stock. Lifesci Capital started coverage on shares of Attovia Therapeutics in a report on Monday. They set an “outperform” rating and a $45.00 price objective for the company. Morgan Stanley began coverage on shares of Attovia Therapeutics in a research report on Monday. They set an “overweight” rating and a $39.00 target price for the company. Finally, Leerink Partners started coverage on shares of Attovia Therapeutics in a report on Monday. They issued an “outperform” rating and a $52.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Attovia Therapeutics presently has a consensus rating of “Buy” and an average price target of $42.20.

Insider Activity

In other Attovia Therapeutics news, major shareholder Goldman Sachs Group Inc bought 500,000 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the insider directly owned 3,020,632 shares in the company, valued at approximately $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio bought 382,352 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $6,499,984.00. Following the transaction, the insider directly owned 4,181,367 shares in the company, valued at approximately $71,083,239. This trade represents a 10.06% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 2,740,587 shares of company stock valued at $47,269,979.

Trending Headlines about Attovia Therapeutics

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: ATTO-1310 showed preliminary proof of concept in chronic pruritus and high-itch atopic dermatitis, supporting the potential of Attovia’s treatment for itch-related inflammatory diseases. The company expects to report complete Phase 1b data in the fourth quarter of 2026. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
• Positive Sentiment: LifeSci Capital initiated coverage with an Outperform rating, adding to bullish sentiment around Attovia’s pipeline and prospects. LifeSci Capital initiates coverage of Attovia Therapeutics with outperform recommendation
• Positive Sentiment: Royal Bank of Canada upgraded Attovia to “Moderate Buy,” reinforcing the positive analyst view following recent clinical progress. Royal Bank of Canada upgrades Attovia Therapeutics
• Neutral Sentiment: Citigroup, Leerink Partners and Royal Bank of Canada also initiated coverage, broadening institutional attention. The articles provided do not specify their initial ratings or price targets. Citigroup initiates coverage Leerink Partners begins coverage Royal Bank of Canada initiates coverage
• Negative Sentiment: Attovia reported a quarterly loss of $4.88 per share, highlighting the company’s ongoing cash-burn and development-stage risk. Attovia second-quarter financial results

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.